Q-omics provides the consensus-scored MEP1B profile across patient tissues and cancer cell-line models. MEP1B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MEP1B is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MEP1B RNA expression shows 13,469 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, COAD, and THYM as cancer lineages where MEP1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEP1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEP1B survival associations across molecular data types. MEP1B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEP1B RNA expression–survival associations across cancer types. High MEP1B expression shows unfavorable associations in ACC, THCA and CHOL, but favorable associations in GBM, LIHC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MEP1B RNA expression.
This table summarizes MEP1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MEP1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEP1B shows lower tumor expression in COAD, LIHC and THCA and higher tumor expression in HNSC, KIRC and BLCA. The COAD box plot shows higher MEP1B RNA expression in normal versus tumor tissue (log2 FC = −3.605, t-test p < 0.001).
This table shows molecular features associated with MEP1B in patient tissues and cancer cell lines. In patient samples, MEP1B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MEP1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
